Home > > > > > Report Detail

Global Hepatocellular Carcinoma Drugs Market Insights, Forecast to 2029

Publisher Name :
Date: 14-Aug-2023
No. of pages: 109
Inquire Before Buying

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

Market Analysis and Insights: Global Hepatocellular Carcinoma Drugs Market

The global Hepatocellular Carcinoma Drugs market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

Report Includes

This report presents an overview of global market for Hepatocellular Carcinoma Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Hepatocellular Carcinoma Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Hepatocellular Carcinoma Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatocellular Carcinoma Drugs revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Hepatocellular Carcinoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Hepatocellular Carcinoma Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Bayer, Eli Lilly, Johnson and Johnson, Pfizer, Bristol-Myers Squibb, Celgene, F. Hoffmann-la Roche, Gilead and GlaxoSmithKline, etc.

By Company

- Bayer

- Eli Lilly

- Johnson and Johnson

- Pfizer

- Bristol-Myers Squibb

- Celgene

- F. Hoffmann-la Roche

- Gilead

- GlaxoSmithKline

- Merck

- Novartis

Segment by Type

- Brachytherapy

- Chemotherapy

- Local Ablation Therapy

Segment by Application

- Hospitals

- Clinics

- Cancer Rehabilitation Centers

By Region

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East, Africa, and Latin America

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Hepatocellular Carcinoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by type, by application and by country, revenue for each segment.

Chapter 7: Europe by type, by application and by country, revenue for each segment.

Chapter 8: China by type and by application revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatocellular Carcinoma Drugs revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Global Hepatocellular Carcinoma Drugs Market Insights, Forecast to 2029

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Brachytherapy
1.2.3 Chemotherapy
1.2.4 Local Ablation Therapy
1.3 Market by Application
1.3.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Rehabilitation Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatocellular Carcinoma Drugs Market Perspective (2018-2029)
2.2 Global Hepatocellular Carcinoma Drugs Growth Trends by Region
2.2.1 Hepatocellular Carcinoma Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hepatocellular Carcinoma Drugs Historic Market Size by Region (2018-2023)
2.2.3 Hepatocellular Carcinoma Drugs Forecasted Market Size by Region (2024-2029)
2.3 Hepatocellular Carcinoma Drugs Market Dynamics
2.3.1 Hepatocellular Carcinoma Drugs Industry Trends
2.3.2 Hepatocellular Carcinoma Drugs Market Drivers
2.3.3 Hepatocellular Carcinoma Drugs Market Challenges
2.3.4 Hepatocellular Carcinoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Hepatocellular Carcinoma Drugs by Players
3.1.1 Global Hepatocellular Carcinoma Drugs Revenue by Players (2018-2023)
3.1.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Hepatocellular Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Hepatocellular Carcinoma Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio
3.4.1 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drugs Revenue in 2022
3.5 Global Key Players of Hepatocellular Carcinoma Drugs Head office and Area Served
3.6 Global Key Players of Hepatocellular Carcinoma Drugs, Product and Application
3.7 Global Key Players of Hepatocellular Carcinoma Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatocellular Carcinoma Drugs Breakdown Data by Type
4.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Type (2018-2023)
4.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029)
5 Hepatocellular Carcinoma Drugs Breakdown Data by Application
5.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Application (2018-2023)
5.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
6.2 North America Hepatocellular Carcinoma Drugs Market Size by Type
6.2.1 North America Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023)
6.2.2 North America Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029)
6.2.3 North America Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
6.3 North America Hepatocellular Carcinoma Drugs Market Size by Application
6.3.1 North America Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023)
6.3.2 North America Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029)
6.3.3 North America Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
6.4 North America Hepatocellular Carcinoma Drugs Market Size by Country
6.4.1 North America Hepatocellular Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)
6.4.3 North America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hepatocellular Carcinoma Drugs Market Size (2018-2029)
7.2 Europe Hepatocellular Carcinoma Drugs Market Size by Type
7.2.1 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023)
7.2.2 Europe Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029)
7.2.3 Europe Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
7.3 Europe Hepatocellular Carcinoma Drugs Market Size by Application
7.3.1 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023)
7.3.2 Europe Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029)
7.3.3 Europe Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
7.4 Europe Hepatocellular Carcinoma Drugs Market Size by Country
7.4.1 Europe Hepatocellular Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)
7.4.3 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Hepatocellular Carcinoma Drugs Market Size (2018-2029)
8.2 China Hepatocellular Carcinoma Drugs Market Size by Type
8.2.1 China Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023)
8.2.2 China Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029)
8.2.3 China Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
8.3 China Hepatocellular Carcinoma Drugs Market Size by Application
8.3.1 China Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023)
8.3.2 China Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029)
8.3.3 China Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Hepatocellular Carcinoma Drugs Market Size (2018-2029)
9.2 Asia Hepatocellular Carcinoma Drugs Market Size by Type
9.2.1 Asia Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023)
9.2.2 Asia Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029)
9.2.3 Asia Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
9.3 Asia Hepatocellular Carcinoma Drugs Market Size by Application
9.3.1 Asia Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023)
9.3.2 Asia Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029)
9.3.3 Asia Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
9.4 Asia Hepatocellular Carcinoma Drugs Market Size by Region
9.4.1 Asia Hepatocellular Carcinoma Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023)
9.4.3 Asia Hepatocellular Carcinoma Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Hepatocellular Carcinoma Drugs Introduction
11.1.4 Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.1.5 Bayer Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Introduction
11.2.4 Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.2.5 Eli Lilly Recent Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Details
11.3.2 Johnson and Johnson Business Overview
11.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Introduction
11.3.4 Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.3.5 Johnson and Johnson Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Hepatocellular Carcinoma Drugs Introduction
11.4.4 Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.4.5 Pfizer Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.5.5 Bristol-Myers Squibb Recent Developments
11.6 Celgene
11.6.1 Celgene Company Details
11.6.2 Celgene Business Overview
11.6.3 Celgene Hepatocellular Carcinoma Drugs Introduction
11.6.4 Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.6.5 Celgene Recent Developments
11.7 F. Hoffmann-la Roche
11.7.1 F. Hoffmann-la Roche Company Details
11.7.2 F. Hoffmann-la Roche Business Overview
11.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Introduction
11.7.4 F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.7.5 F. Hoffmann-la Roche Recent Developments
11.8 Gilead
11.8.1 Gilead Company Details
11.8.2 Gilead Business Overview
11.8.3 Gilead Hepatocellular Carcinoma Drugs Introduction
11.8.4 Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.8.5 Gilead Recent Developments
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Introduction
11.9.4 GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.9.5 GlaxoSmithKline Recent Developments
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Hepatocellular Carcinoma Drugs Introduction
11.10.4 Merck Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.10.5 Merck Recent Developments
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Hepatocellular Carcinoma Drugs Introduction
11.11.4 Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)
11.11.5 Novartis Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Brachytherapy
Table 3. Key Players of Chemotherapy
Table 4. Key Players of Local Ablation Therapy
Table 5. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Hepatocellular Carcinoma Drugs Market Share by Region (2018-2023)
Table 9. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Hepatocellular Carcinoma Drugs Market Share by Region (2024-2029)
Table 11. Hepatocellular Carcinoma Drugs Market Trends
Table 12. Hepatocellular Carcinoma Drugs Market Drivers
Table 13. Hepatocellular Carcinoma Drugs Market Challenges
Table 14. Hepatocellular Carcinoma Drugs Market Restraints
Table 15. Global Hepatocellular Carcinoma Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Hepatocellular Carcinoma Drugs Revenue Share by Players (2018-2023)
Table 17. Global Top Hepatocellular Carcinoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)
Table 18. Global Hepatocellular Carcinoma Drugs Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Hepatocellular Carcinoma Drugs, Headquarters and Area Served
Table 21. Global Key Players of Hepatocellular Carcinoma Drugs, Product and Application
Table 22. Global Key Players of Hepatocellular Carcinoma Drugs, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2024-2029)
Table 28. Global Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Hepatocellular Carcinoma Drugs Revenue Share by Application (2018-2023)
Table 30. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Hepatocellular Carcinoma Drugs Revenue Share by Application (2024-2029)
Table 32. North America Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America Hepatocellular Carcinoma Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe Hepatocellular Carcinoma Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 46. China Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 48. China Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia Hepatocellular Carcinoma Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Hepatocellular Carcinoma Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 64. Bayer Company Details
Table 65. Bayer Business Overview
Table 66. Bayer Hepatocellular Carcinoma Drugs Product
Table 67. Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 68. Bayer Recent Developments
Table 69. Eli Lilly Company Details
Table 70. Eli Lilly Business Overview
Table 71. Eli Lilly Hepatocellular Carcinoma Drugs Product
Table 72. Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 73. Eli Lilly Recent Developments
Table 74. Johnson and Johnson Company Details
Table 75. Johnson and Johnson Business Overview
Table 76. Johnson and Johnson Hepatocellular Carcinoma Drugs Product
Table 77. Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 78. Johnson and Johnson Recent Developments
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Hepatocellular Carcinoma Drugs Product
Table 82. Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 83. Pfizer Recent Developments
Table 84. Bristol-Myers Squibb Company Details
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Product
Table 87. Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Developments
Table 89. Celgene Company Details
Table 90. Celgene Business Overview
Table 91. Celgene Hepatocellular Carcinoma Drugs Product
Table 92. Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 93. Celgene Recent Developments
Table 94. F. Hoffmann-la Roche Company Details
Table 95. F. Hoffmann-la Roche Business Overview
Table 96. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Product
Table 97. F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 98. F. Hoffmann-la Roche Recent Developments
Table 99. Gilead Company Details
Table 100. Gilead Business Overview
Table 101. Gilead Hepatocellular Carcinoma Drugs Product
Table 102. Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 103. Gilead Recent Developments
Table 104. GlaxoSmithKline Company Details
Table 105. GlaxoSmithKline Business Overview
Table 106. GlaxoSmithKline Hepatocellular Carcinoma Drugs Product
Table 107. GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 108. GlaxoSmithKline Recent Developments
Table 109. Merck Company Details
Table 110. Merck Business Overview
Table 111. Merck Hepatocellular Carcinoma Drugs Product
Table 112. Merck Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 113. Merck Recent Developments
Table 114. Novartis Company Details
Table 115. Novartis Business Overview
Table 116. Novartis Hepatocellular Carcinoma Drugs Product
Table 117. Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)
Table 118. Novartis Recent Developments
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Hepatocellular Carcinoma Drugs Market Share by Type: 2022 VS 2029
Figure 3. Brachytherapy Features
Figure 4. Chemotherapy Features
Figure 5. Local Ablation Therapy Features
Figure 6. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Hepatocellular Carcinoma Drugs Market Share by Application: 2022 VS 2029
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Cancer Rehabilitation Centers Case Studies
Figure 11. Hepatocellular Carcinoma Drugs Report Years Considered
Figure 12. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Hepatocellular Carcinoma Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Hepatocellular Carcinoma Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Hepatocellular Carcinoma Drugs Market Share by Players in 2022
Figure 16. Global Top Hepatocellular Carcinoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Drugs Revenue in 2022
Figure 18. North America Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
Figure 20. North America Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
Figure 21. North America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
Figure 22. United States Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Hepatocellular Carcinoma Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 25. Europe Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
Figure 26. Europe Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
Figure 27. Europe Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
Figure 28. Germany Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. China Hepatocellular Carcinoma Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 35. China Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
Figure 36. China Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
Figure 37. Asia Hepatocellular Carcinoma Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 38. Asia Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
Figure 39. Asia Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
Figure 40. Asia Hepatocellular Carcinoma Drugs Market Share by Region (2018-2029)
Figure 41. Japan Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. South Korea Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. China Taiwan Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Southeast Asia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. India Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Australia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Share by Type (2018-2029)
Figure 49. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Share by Application (2018-2029)
Figure 50. Middle East, Africa, and Latin America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)
Figure 51. Brazil Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Mexico Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Turkey Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Saudi Arabia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Israel Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. GCC Countries Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 58. Eli Lilly Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 59. Johnson and Johnson Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 60. Pfizer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 62. Celgene Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 63. F. Hoffmann-la Roche Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 64. Gilead Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 65. GlaxoSmithKline Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 66. Merck Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 67. Novartis Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs